SimBioSys Gains FDA Clearance for TumorSight Viz in Breast Cancer Surgery

SimBioSys has secured its third FDA 510(k) clearance for TumorSight Viz, an AI-powered platform designed to enhance precision in breast cancer surgery, announced in a press release. This latest version, TumorSight Viz 1.3, introduces advanced features such as superior AI-driven segmentation and faster case processing, which aim to improve preoperative planning and streamline surgical workflows.

The platform converts standard breast MRI into intuitive 3D visualizations, supporting more informed surgical decision-making. With its new capabilities, TumorSight Viz 1.3 enhances surgeon usability and integrates seamlessly into existing workflows, offering same-day insights for timely patient consultations.

SimBioSys emphasizes that TumorSight Viz 1.3 is clinically validated, with studies showing strong concordance with radiologist annotations and consistent performance across multiple institutions. This clearance marks a significant step in providing surgeons with tools that offer greater clarity and control in breast cancer surgery, ultimately aiming to improve patient outcomes.